The Impact of IL28B Gene Polymorphisms on Drug Responses
Tran Nhan Phan,Dp Thi Le Hang,Vu Thi Thom,Dinh Doan Long,Pham Thi Hong Nhung
DOI: https://doi.org/10.25073/2588-1132/vnumps.4289
2021-12-05
Abstract:To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and technology, especially genetic sequencing technology, more and more research on pharmacogenomics has been conducted. The relationship between the genome and the response of a person to drugs is being explored to support personalized medicine, which shows efficacy in clinical treatment. In particular, the IL28B gene polymorphisms have been studied and shown to have impacts on drug responses in the treatment of many diseases, such as chronic hepatitis C, chronic hepatitis B, and myeloproliferative neoplasms. However, pharmacogenetic studies of the IL28B gene have not given exact recommendations for dose adjustment in treatment; they only show the impact tendency that individuals with an unfavorable genotype (usually the genotype of the mutant allele) show poor response to treatment compared to those with a favorable genotype. The frequency of mutant alleles varies among different ethnic groups and between different viral genotypes. Identifying and predicting the possibility of successful treatment helps both clinicians and patients make better choices of treatment decisions to optimize treatment possibilities, and reduce side effects and treatment costs.
Keywords
IL28B polymorphism, drug response, hepatitis C, hepatitis B, myeloproliferative disorders.
References
[1] V. M. Lauschke, M. I. Sundberg, The Importance of Patient - Specific Factors for Hepatic Drug Response and Toxicity, International Journal of Molecular Sciences, Vol. 17, No. 10, 2016, pp. 1714, https://doi.org/10.3390/ijms17101714.[2] E. Vesell et al., Genetic and Environmental Factors Affecting Drug Disposition in man, Clinical Pharmacology & Therapeutics, Vol. 22, No. 5, 1977, pp. 659-679, https://doi.org/10.1002/cpt1977225part2659.[3] M. J Sorich, R. A McKinnon, Personalized Medicine: Potential, Barriers and Contemporary Issues, Current Drug Metabolism, Vol. 13, No. 7, 2012, pp. 1000-1006, https://doi.org/10.2174/138920012802138615.[4] C. M. Lange, S. Zeuzem, IL28B Single Nucleotide Polymorphisms in the Treatment of Hepatitis C, Journal of Hepatology, Vol. 55, No. 3, 2011, pp. 692-701, https://doi.org/10.1016/j.jhep.2011.03.006.[5] Y. Luo, C. Jin, Z. Ling, X. Mou, Q. Zhang, C. Xiang, Association Study of IL28B: Rs12979860 and Rs8099917 Polymorphisms With SVR in Patients Infected with Chronic HCV Genotype 1 to PEG-INF/RBV Therapy using Systematic Meta-Analysis, Gene, Vol. 513, No. 2, 2013, pp. 292-296, https://doi.org/10.1016/j.gene.2012.10.030.[6] A. Muir et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐Α-Based Regimens, Clinical Pharmacology Therapeutics, Vol. 95, No. 2, 2014, pp. 141-146, https://doi.org/10.1038/clpt.2013.203.[7] The Pharmacogenomics Knowledgebase (PharmGKB), Drug Label Annotations, https://www.pharmgkb.org/gene/PA134952671/labelAnnotation/, 2020 (accessed on: April 10th, 2020).[8] A. Jazwinski, A. Muir, IL28B: Implications for Clinical Practice, Current Hepatitis Reports, Vol. 11, No. 1, 2012, pp. 15-22, https://doi.org/10.1007/s11901-011-0118-y.[9] Ensembl, Variant Table https://asia.ensembl.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g=ENSG00000197110;r=19:39243553-39245129/, 2020 (accessed on: April 20th, 2020).[10] Ensembl, Explore This Variant, https://asia.ensembl.org/index.html/,02020 2020 (accessed on: April 20th, 2020).[11] Ministry of Health, Technical Guidelines on HCV Diagnosis and Treatment, Ministry of Health, Hanoi, 2016 (in Vietnamese).[12] A. J. V. D. Meer et al., Association between Sustained Virological Response and All-Cause Mortality Among Patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis, Jama, Vol. 308, No. 24, 2012, pp. 2584-2593, https://doi.org/10.1001/jama.2012.144878.[13] J. J. Feld, J. H. Hoofnagle, Mechanism of Action of Interferon and Ribavirin in Treatment of Hepatitis C, Nature Genetics, Vol. 436, No. 7053, 2005, pp. 967-972, https://doi.org/10.1038/nature04082.[14] D. Ge et al., Genetic Variation in IL28B Predicts Hepatitis C Treatment-Induced Viral Clearance, Nature Genetics, Vol. 461, No. 7262, 2009, pp. 399-401, https://doi.org/10.1038/nature08309.[15] J. Fischer et al., Combined Effects of Different Interleukin‐28B Gene Variants on the Outcome of Dual Combination Therapy in Chronic Hepatitis C Virus Type 1 Infection, Hepatology, Vol. 55, No. 6, 2012, pp. 1700-1710, https://doi.org/10.1002/hep.25582.[16] E. Cariani et al., Interleukin 28B Polymorphisms As Predictors of Sustained Virological Response in Chronic Hepatitis C: Systematic Review and Meta-Analysis, The Pharmacogenomics Journal, Vol. 16, No. 1, 2016, pp. 18-29, https://doi.org/10.1038/tpj.2015.28.[17] Z. Jia, Y. Ding, S. Tian, J. Niu, J. Jiang, Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with Pegifn and Ribavirin Depends on HCV Genotypes: Results from A Meta-Analysis, Plos One, Vol. 7, No. 9, 2012, pp. e45698, https://doi.org/10.1371/journal.pone.0045698.[18] A. Moghaddam et al., IL28B Genetic Variation and Treatment Response in Patients with Hepatitis C Virus Genotype 3 Infection, Hepatology, Vol. 53, No. 3, 2011, pp. 746-754, https://doi.org/10.1002/hep.24154.[19] E. Mohammed et al., IFNL3 Polymorphisms Predict Response to Therapy in Chronic Hepatitis C Genotype 2/3 Infection, Journal of Hepatology, Vol. 61, No.2, 2014, pp. 235-241, https://doi.org/10.1016/j.jhep.2014.03.039.[20] T. M. Scherzer et al., Early Virologic Response and IL28B Polymorphisms in Patients with Chronic Hepatitis C Genotype 3 Treated with Peginterferon Alfa-2a and Ribavirin, Journal of Hepatology, Vol. 54, No. 5, 2011, pp. 866-871, https://doi.org/10.1016/j.jhep.2010.08.024.[21] J. Stenkvist, A. Sönnerborg, O. Weiland, HCV RNA Decline in Chronic HCV Genotype 2 and 3 During Standard of Care Treatment According to IL28B Polymorphism, Journal of Viral Hepatitis, Vol. 20, No. 3, 2013, pp. 193-199, https://doi.org/10.1111/j.1365-2893.2012.01645.x.[22] T. Asselah et al., IL28B Polymorphism is Associated with Treatment Response in Patients with Genotype 4 Chronic Hepatitis C, Journal of Hepatology, Vol. 56, No. 3, 2012, pp. 527-532, https://doi.org/10.1016/j.jhep.2011.09.008.[23] S. D. Nicola et al., Interleukin 28B Polymorphism Predicts Pegylated Interferon Plus Ribavirin Treatment Outcome in Chronic Hepatitis C Genotype 4, Hepatology, Vol. 55, No. 2, 2012, pp. 336-342, https://doi.org/10.1002/hep.24683.[24] M. Derbala et al., Interleukin-28 and Hepatitis C Virus Genotype-4: Treatment-Induced Clearance and Liver Fibrosis, World Journal of Gastroenterology, Vol. 18, No. 47, 2012, pp. 7003-7008, https://doi.org/10.3748/wjg.v18.i47.7003.[25] N. Antaki et al., IL28B Polymorphisms do not Predict Response to Therapy in Chronic Hepatitis C with HCV Genotype 5, Gut, Vol. 61, No. 11, 2012, pp. 1640-1641, http://dx.doi.org/10.1136/gutjnl-2012-302019.[26] S. Akkarathamrongsin et al., Early Viral Kinetics During Hepatitis C Virus Genotype 6 Treatment According to IL28B Polymorphisms, World Journal of Gastroenterology, Vol. 20, No. 30, 2014, pp. 10599-10605, https://doi.org/10.3748/wjg.v20.i30.10599.[27] C. Bucci et al., Favourable IL28B Polymorphisms Are Associated with A Marked Increase in Baseline Viral Load In Hepatitis C Virus Subtype 3a Infection and Do Not Predict A Sustained Virological Response After 24 Weeks of Therapy, Journal of General Virology, Vol. 94, No. 6, 2013, pp. 1259-1265, https://doi.org/10.1099/vir.0.051052-0.[28] M. L. Yu et al., Role of Interleukin‐28B Polymorphisms in the Treatment of Hepatitis C Virus Genotype 2 Infection in Asian Patients, Hepatology, Vol. 53, No. 1, 2011, pp. 7-13, https://doi.org/10.1002/hep.23976.[29] O. G. Shaker, N. A. Sadik, Polymorphisms in Interleukin‐10 and Interleukin‐28 B Genes in E Gyptian Patients with Chronic Hepatitis C Virus Genotype 4 and Their Effect on the Response to Pegylated Interferon/Ribavirin‐Therapy, Journal of Gastroenterology Hepatology, Vol. 27, No. 12, 2012, pp. 1842-1849, https://doi.org/10.1111/j.14401746.2012.07273.x.[30] W. K. Seto et al., Role of IL 28B and Inosine Triphosphatase Polymorphisms in the Treatment of Chronic Hepatitis C Virus Genotype 6 Infection, Journal of Viral Hepatitis, Vol. 20, No. 7, 2013, pp. 470-477, https://doi.org/10.1111/jvh.12047.[31] H. Zheng, M. Li, B. Chi, X. X. Wu, J. Wang, D. W. Liu, IL28B Rs12980275 Variant As A Predictor of Sustained Virologic Response to Pegylated-Interferon and Ribavirin in Chronic Hepatitis C Patients: A Systematic Review and Meta-Analysis, Clinics Research in Hepatology Gastroenterology, Vol. 39, No. 5, 2015, pp. 576-583, https://doi.org/10.1016/j.clinre.2015.01.009.[32] J. Chen et al., IL28B Genetic Variations Are Associated with High Sustained Virological Response (SVR) of Interferon-Α Plus Ribavirin Therapy in Taiwanese Chronic HCV Infection, Genes Immunity, Vol. 12, No. 4, 2011, pp. 300-309, https://doi.org/10.1038/gene.2011.1.[33] Y. Tanaka et al., Genome-Wide Association of IL28B with Response to Pegylated Interferon-Α and Ribavirin Therapy for Chronic Hepatitis C, Nature Genetics, Vol. 41, No. 10, 2009, pp. 1105-1109, https://doi.org/10.1038/ng.449.[34] [34] M. P. Vincent Soriano et al., Care Of Patients Coinfected with HIV and Hepatitis C Virus: 2007 Updated Recommendations from the HCV-HIV International Panel, Aids, Vol. 21, No. 9, 2007, pp. 1073-1089, https://doi.org/10.1097/QAD.0b013e3281084e4d.[35] C. S. Graham et al, Influence of Human Immunodeficiency Virus Infection on the Course of Hepatitis C Virus Infection: A Meta-Analysis, Clinical Infectious Diseases, Vol. 33, No. 4, 2001, pp. 562-569, https://doi.org/10.1086/321909.[36] M. D. Castellarnau et al., Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-Α And Ribavirin Therapy in HCV/HIV-1 Coinfected Patients, Plos One, Vol. 7, No. 2, 2012, pp. e31016, https://doi.org/10.1371/journal.pone.0031016.[37] I. M. Jacobson et al., Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection, The New England Journal of Medicine, Vol. 364, No. 25, 2011, pp. 2405-2416, https://doi.org/10.1056/NEJMoa1012912.[38] V. Vadwai, B. R. Das, IL28B Genotyping: A Step Towards HCV-Personalized Therapy, International Journal of Gastroenterology Research and Practice, Vol. 2014, No. 2014, pp. 16, https://doi.org/10.5171/2014.212341.[39] F. About et al., Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety pf TVR-Or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study, PloS One, Vol. 10, No. 12, 2015, pp. e0145105, https://doi.org/10.1371/journal.pone.0145105.[40] G. Calisti et al., IL28B Genotype Predicts Response to Chronic Hepatitis C Triple Therapy with Telaprevir or Boceprevir in Treatment Naïve and Treatment-Experienced Patients Other Than Prior Partial-and Null-Responders, Springer Plus, Vol. 4, No. 1, 2015, pp. 1-9, https://doi.org/10.1186/s40064-015-1137-x.[41] S. Susser et al., Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C, Plos One, Vol. 9, No. 11, 2014, pp. e112592, https://doi.org/10.1371/journal.pone.0112592.[42] A. Tsubota et al., Impact of IL28B Polymorphisms on 24‐Week Telaprevir‐Based Combination Therapy for A Sian Chronic Hepatitis C Patients with Hepatitis C Virus Genotype 1b, Journal of Gastroenterology Hepatology, Vol. 29, No. 1, 2014, pp. 144-150, https://doi.org/10.1111/jgh.12402.[43] M. Manns et al., Simeprevir with Pegylated Interferon Alfa 2a or 2b Plus Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Genotype 1 Infection (QUEST-2): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial, The Lancet, Vol. 384, No. 9941, 2014, pp. 414-426, https://doi.org/10.1016/S0140-6736(14)60538-9.[44] M. Nakayama, H. Kobayashi, K. Fukushima, M. Ishido, Y. Komada, K. Yoshizawa, Predictive Factors for 24 Weeks Sustained Virologic Response (SVR24) and Viral Relapse in Patients Treated with Simeprevir Plus Peginterferon and Ribavirin, Hepatology International, Vol. 10, No. 1, 2016, pp. 158-168, https://doi.org 10.1007/s12072-015-9654-9.[45] F. Poordad et al., Factors that Predict Response of Patients with Hepatitis C Virus Infection to Boceprevir, Gastroenterology, Vol. 143, No. 3, 2012, pp. 608-618, https://doi.org/10.1053/j.gastro.2012.05.011.[46] C. Hézode et al., Daclatasvir Plus Peginterferon Alfa and Ribavirin for Treatment-Naive Chronic Hepatitis C Genotype 1 or 4 Infection: A Randomised Study, Gut, Vol. 64, No. 6, 2015, pp. 948-956, http://dx.doi.org/10.1136/gutjnl-2014-307498.[47] A Thompson et al., GS-5885 + GS-9451 + Peginterferon and Ribavrin (Pr) for Six or 12 Weeks Achieves A High SVR12 in Treatment Naïve Genotype 1 IL28B CC Patients, Journal of Hepatology, Vol. 58, No. Suppl 1, 2013, pp. S29, https://doi.org/10.1016/S0168-8278(13)60066-5.[48] S. Zeuzem et al., Pegylated Interferon-Lambda (Pegifn-Λ) Shows Superior Viral Response with Improved Safety and Tolerability Versus Pegifn-Α-2a In HCV Patients (G1/2/3/4): EMERGE Phase Iib Through Week 12, Journalof Hepatology, Vol. 54, No. Suppl 1, 2011, pp. S538, https://doi.org/10.1016/S0168-8278(11)61362-7.[49] S. Zeuzem et al., Faldaprevir and Deleobuvir for HCV Genotype 1 Infection, The New England Journal of Medicine, Vol. 369, No. 7, 2013, pp. 630-639, https://doi.org/10.1056/NEJMoa1213557.[50] T. R. O'Brien, S. Kottilil, J. J. Feld, T. R. Morgan, R. M. Pfeiffer, Race or Genetic Makeup for Hepatitis C Virus Treatment Decisions?, Hepatology, Vol. 65, No. 6, 2017, pp. 2124-2125, https://doi.org/10.1002/hep.29057.[51] R. M. Pfeiffer et al, Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C, Open Forum Infectious Diseases, Vol. 1, No. 3, 2014, pp.1-4 ofu110, https://doi.org/10.1093/ofid/ofu110.[52] N. Akuta et al., Retreatment Efficacy and Predictors of Ledipasvir Plus Sofosbuvir to HCV Genotype 1 in Japan, Journal of Medical Virology, Vol. 89, No. 2, 2017, pp. 284-290, https://doi.org/10.1002/jmv.24617.[53] T. R. O’Brien, S. Kottilil, R. M. Pfeiffer, IFNL4 Genotype is Associated with Virologic Relapse After 8-Week Treatment with Sofosbuvir, Velpatasvir, and Voxilaprevir, Gastroenterology, Vol. 153, No. 6, 2017, pp. 1694-1695, https://doi.org/10.1053/j.gastro.2017.06.069.[54] A. J. Khan, V. A. Saraswat, P. Ranjan, D. Parmar, T. S. Negi, S. Mohindra, Polymorphism in Interferon Λ3/Interleukin‐28B Gene and Risk to Noncirrhotic Chronic Hepatitis C Genotype 3 Virus Infection and Its Effect on the Response to Combined Daclatasvir and Sofosbuvir Therapy, Journal of Medical Virology, Vol. 91, No. 4, 2019, pp. 659-667, https://doi.org/10.1002/jmv.25359.[55] A. Vasanthakumar et al., Reduced Itpase Activity and Favorable Il28b Genetic Variant Protect Against Ribavirin-Induced Anemia in Interferon-Free Regimens, Plos One, Vol. 13, No. 5, 2018, pp. e0198296, https://doi.org/10.1371/journal.pone.0198296.[56] H. Ahmed et al., Meta-Analysis of Grazoprevir Plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection, Annals of Hepatology, Vol. 17, No. 1, 2018, pp. 18-32, https://doi.org/10.5604/01.3001.0010.7532 [57] J. J. Feld et al., Treatment of HCV with ABT-450/R–Ombitasvir and Dasabuvir with Ribavirin, New England Journal of Medicine, Vol. 370, No. 17, 2014, pp. 1594-1603, https://doi.org/10.1056/NEJMoa1315722.[58] S. Padmanabhan, Handbook of Pharmacogenomics and Stratified Medicine, Elsevier, London, 2014.[59] A. Osinusi, S. Naggie, The Role of IL28B Genotype Testing in The Era of Direct Acting Antiviral Agents, European Gastroenterology Hepatology Review, Vol. 1, No. 2, 2012, pp. 33-39. [60] Ministry of Health, Technical Guidelines on HBV Diagnosis and Treatment, Ministry of Health, Hanoi, 2019 (in Vietnamese).[61] Y. Yano et al., Factors Associated with the Decrease in Hepatitis B Surface Antigen Titers Following Interferon Therapy in Patients with Chronic Hepatitis B: Is Interferon and Adefovir Combination Therapy Effective?, Biomedical Reports, Vol. 7, No. 3, 2017, pp. 257-262, https://doi.org/10.3892/br.2017.944.[62] H. L. Y. Chan et al., A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-Α2b and Lamivudine with Lamivudine Alone, Annals Of Internal Medicine, Vol. 142, No. 4, 2005, pp. 240-250, https://doi.org/10.7326/0003-4819-142-4-200502150-00006.[63] H. L. Janssen et al., Pegylated Interferon Alfa-2b Alone or in Combination with Lamivudine for Hbeag-Positive Chronic Hepatitis B: A Randomised Trial, The Lancet, Vol. 365, No. 9454, 2005, pp. 123-129, https://doi.org/10.1016/S0140-6736(05)17701-0.[64] G. K. Lau et al., Peginterferon Alfa-2a, Lamivudine, and The Combination for Hbeag-Positive Chronic Hepatitis B, New England Journal of Medicine, Vol. 352, No. 26, 2005, pp. 2682-2695, https://doi.org/10.1056/NEJMoa043470.[65] Z. Zhao et al., The Impact Of IFNL3 Genotype on Interferon Treatment Outcome in Patients Chronically Infected with Hepatitis B Virus: A Meta-Analysis, Microbial Pathogenesis, Vol. 134, 2019, pp. 103598, https://doi.org/10.1016/j.micpath.2019.103598.[66] M. Lindgren et al., Genetic Variation in IL 28B (IFNL 3) and Response to Interferon‐Alpha Treatment in Myeloproliferative Neoplasms, European Journal of Haematology, Vol. 100, No. 5, 2018, pp. 419-425, https://doi.org/10.1111/ejh.13034.[67] P. J. Campbell, A. R. Green, The Myeloproliferative Disorders, New England Journal of Medicine, Vol. 355, No. 23, 2006, pp. 2452-2466, https://doi.org/10.1056/NEJMra063728.[68] R. T. Silver, J. J. Kiladjian, H. C. Hasselbalch, Interferon and The Treatment of Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis, Expert Rev Hematol, Vol. 6, No. 1, 2013, pp. 49-58, https://doi.org/10.1586/ehm.12.69.[69] R. T. Silver, K. Vandris, J. J. Goldman, Recombinant Interferon-Alpha May Retard Progressionof Early Primary Myelofibrosis: A Preliminary Report, Blood, Vol. 117, No. 24, 2011, pp. 6669-6672, https://doi.org/10.1182/blood-2010-11-320069.[70] M. Lindgren et al., A Retrospective Cohort Study of Interferon-Α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy, Blood, Vol. 124, No. 21, 2014, pp. 1861, https://doi.org/10.1182/blood.V124.21.1861.1861.[71] P. H. Phiet et al., Rs12979860 and Rs8099917 Single Nucleotide Polymorphism of IL28B Gene in South Vietnam Patients Infected with Hepatitis C Virus, Journal of Hepatobiliary Vietnam, Vol. 21, 2012, pp. 9-16 (in Vietnamese).[72] P. T. T. Thuy et al., The Different Impacts of IL28B Genotype in Treatment Vietnamese Patients with Chronic Hepatitis C Genotype 1 and 6, Journal of Hepatobiliary Vietnam, Vol. 29, 2014, pp. 108-109 (in Vietnamese).
What problem does this paper attempt to address?
-
Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis
Zhifang Jia,Yanhua Ding,Suyan Tian,Junqi Niu,Jing Jiang
DOI: https://doi.org/10.1371/journal.pone.0045698
IF: 3.7
2012-01-01
PLoS ONE
Abstract:BACKGROUND:Many studies have been published on the association between single nucleotide polymorphisms (SNP) near the IL28B gene and response to the combined treatments of pegylated-interferon (PegIFN) and ribavirin (RBV) in chronic HCV-infected patients, but without identical conclusions. The aim of this study was to assess impact of the IL28B polymorphisms on the effect of HCV standard treatment using meta-analysis based method. METHODS:Association studies between polymorphisms of rs12979860 or rs8099917 and response to PegIFN/RBV treatment in chronic HCV patients were retrieved from PubMed. Data of qualified studies on sustained virological response (SVR) in different genotypes were extracted and analyzed using meta-analysis method in Stata 10 software. RESULTS:Thirty-four papers, containing 46 independent studies, were included in the analysis. In the HCV G1/4 patients without treatment history, individuals carrying rs12979860 CC genotype were more likely to achieve SVR (OR 3.97, 95%CI 3.29-4.80) compared to those carrying CT/TT genotypes. Similar results were observed in the HCV G1/4 patients with unsuccessful or unknown treatment history (OR 3.76, 95%CI 2.67-5.28) or in the patients co-infected with human immunodeficiency virus (OR 5.20, 95%CI 3.04-8.90). However, associations could not be observed in HCV G2/3 patients. For rs8099917, similar results were obtained for genotype TT compared to genotypes TG/GG, indicating that TT genotype was significantly associated with better treatment response in patients infected with genotype 1 or 4 HCV, but not genotype 2 or 3 HCV. CONCLUSION:Polymorphisms of rs12979860 and rs8099917 near IL28B only associate with the treatment response to PegIFN/RBV in patients infected with HCV genotype 1 or 4 but not with genotype 2 or 3, irrespective of the previous treatment history or HIV co-infected status. Therefore, identification of IL28B genotypes is necessary only in patients infected with relatively difficult-to-treat genotype 1 or 4 HCV.
-
Relationship Between the Genetic Variation in Interleukin 28b and Response to Antiviral Therapy in Patients with Chronic Hepatitis C
Xie Jun-qiang,Guo Xiao-yan,Zhang Xiao-hong,Lin Bing-liang,Xie Dong-ying,Gao Zhi-liang,Wang Gen-shu,Zhao Zhi-xin
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2012.13.017
2012-01-01
Abstract:Background Genetic variations at the interleukin 28B (IL-28B) locus are important in predicting outcome following therapy for chronic hepatitis C virus (HCV) infection. The aim of this research was to evaluate the role of IL-28B single nucleotide polymorphism (SNP) variations in Chinese patients undergoing pegylated interferon-a plus ribavirin (PEG-IFN-alpha/RBV) treatment.Methods To determine the effect of IL-288 variation on the response to HCV therapy, these variants were genotyped in a cohort of 220 patients who were chronically infected with HCV and received combined PEG-IFN-a/RBV therapy.Results The proportions of rs12979860 CC, CT, and TT genotypes were 71.4%, 25.0%, and 3.6% respectively, in the sustained virological response (SVR) group; 15.8%, 60.5%, and 23.7% respectively, in the null virological response (NVR) group; and 38.1%, 52.4%, and 9.5% respectively, in the relapse (Rel) group (P<0.05). Logistic regression analysis showed that, compared to those having the CC genotype, CT heterozygotes had an increased risk of NVR and Rel (OR=10.95, 95% Cl =4.12-29.11, P=1.5x10(-7) and OR=3.93, 95% CI =1.86-8.32, P=2.1x10(-4) respectively). The RNA quantification assay showed that patients with genotype CC exhibited much higher levels of IL-28 expression than those with genotype CT or TT (P <0.001).Conclusions The IL-28B SNP rs12979860 genotype was related to the effectiveness of HCV therapy: patients with the CC rs12979860 genotype had higher rates of SVR than those with the CT or TT genotype, and the CC genotype revealed a significantly higher level of IL-28 mRNA expression. Chin Med J 2012;125(13):2334-2338
-
The effects of interleukin-28B gene polymorphisms on antiviral treatment response in patients with chronic hepatitis C
Yu Zhou,X. Ye,Wei Chen,L. Hong
DOI: https://doi.org/10.3760/CMA.J.ISSN.1000-6680.2017.04.007
2017-04-15
Abstract:Objective
To investigate the relationship between interleukin (IL)-28B gene polymorphisms (rs12979860 and rs8099917) and treatment response in patients with chronic hepatitis C in China.
Methods
Taqman probes single nucleotide polymorphism genotyping methods were used to detect the genotypes of rs12979860 (C/T) and rs8099917 (T/G) located at IL-28B gene in 105 included patients. The patients were treated with standard doses of pegylated interferon plus ribavirin and were followed up regularly for therapeutic response and adverse reaction. The relationship between IL-28B gene polymorphism and antiviral treatment response of patients were analyzed. Categorical data were analyzed using Pearson chi-square test or Fisher exact test.
Results
Totally 105 cases were included in our study and 2 cases lost to follow-up because of moving away. Eight-one cases (78.6%) of the remaining 103 patients were CC/TT genotype (CC/TT group) at rs12979860 and rs8099917, 19 cases (18.4%) were CT/TG (CT/TG group) and 3 cases (2.9%)were TT/TG (TT/TG group). No other genotypes were detected and linkage disequilibrium was discovered at the two polymorphism loci (r2=0.11). After 4 weeks of treatment, 35 cases (43.2%) in CC/TT group, 3 cases (15.8%) in CT/TG group and non in TT/TG group achieved rapid virological response (RVR). There were statistically significant differences among three groups (P=0.033). After 12 weeks of treatment, 45 cases (55.6%) in CC/TT group, 6 cases (31.6%) in CT/TG group and none in TT/TG group achieved early virological response (EVR). There were statistically significant differences among three groups (P=0.025). At the end of the treatment, 68 cases (83.9%) in CC/TT group, 10 cases (52.6%) in CT/TG group and only 1 case (33.3%) in TT/TG group achieved end-of-treatment response (ETR). There were significant statistical differences among the three groups (P=0.003). After 24 weeks of follow-up, 62 cases (76.5%) in CC/TT group, 9 cases (47.4%) in CT/TG group and 1 case (33.3%) in TT/TG group achieved sustained virological response (SVR). There were statistically significant differences among the three groups (P=0.014). One hundred and one cases in CC/TT group developed adverse events, among them 19 cases needed clinical treatment. There were 43 cases in CT/TG group developed adverse events and 9 cases needed treatment. Seven cases in TT/TG group developed adverse events and only 1 case needed treatment. There were no statistically significant difference among three groups (χ2=0.139, P>0.05).
Conclusions
The genotype of rs12979860 (C/T) and rs8099917 (T/G) at IL-28B gene could affect the treatment response in patients with chronic hepatitis C. RVR and SVR are higher in patients with genotype CC/TT, which might help to guide HCV treatment.
Key words:
Interleukin-28B; Hepatitis C, chronic; Polymorphism, single nucleotide; Antiviral response
Medicine
-
[Genetic Polymorphisms of IL-28B Are Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C].
Jun-qiang Xie,Xiao-yan Guo,Hong Cao,Xiao-hong Zhang,Dong-ying Xie,Zhi-liang Gao,Zhi-xin Zhao
DOI: https://doi.org/10.3760/cma.j.issn.1007-3418.2012.12.004
2012-01-01
Abstract:OBJECTIVE:To explore the relationship between polymorphism in the interleukin (IL)-28B gene and sustained virologic response (SVR) in chronic hepatitis C (CHC) patients.METHODS:A total of 220 patients with CHC were prospectively treated with pegylated-interferon (peg-IFN) in combination with ribavirin (RBV) for 48 weeks, and followed-up for an additional 24 weeks. All patients were genotyped for the rs8099917 polymorphism and correlations with antiviral efficacy were determined by statistical analysis.RESULTS:One-hundred-and-eighty-two (82.7%) of the patients achieved end-of-treatment virological response (ETVR). Significantly more patients in the ETVR group carried the rs8099917 genotypes of TT (93.5%) and GT+GG (68.8%), compared to the patients who did not achieve ETVR (X2=23.287, P less than 0.01). In addition, the patients who achieved SVR also represented significantly higher rates of both genotypes (TT: 86.2% and GT+GG: 60.6%; X2=15.531, P less than 0.01). In the SVR group: TT vs. GT+GG: odds ratio (OR)=4.063, 95% confidence interval (CI): 1.972-8.369; X2=15.531, P less than 0.01. In the RP group: TT vs. GT+GG: OR=0.246, 95% CI: 0.119-0.507; X2=15.531, P less than 0.01).CONCLUSION:The IL-28B rs8099917 genotype is closely related to antiviral response of patients with chronic hepatitis C. Compared to carriers of the GT and GG genotypes, carriers of the TT genotype have higher SVR rates and lower RP rates. The TT genotype may be an important predictor of antiviral efficacy.
-
Association of Single Nucleotide Polymorphisms in Interferon Signaling Pathway Genes and Interferon-Stimulated Genes with the Response to Interferon Therapy for Chronic Hepatitis C
Xiaowen Su,Leland J. Yee,KyungAh Im,Shannon L. Rhodes,YongMing Tang,Xiaomei Tong,Charles Howell,Darmendra Raincharran,Hugo R. Rosen,Milton W. Taylor,T. Jake Liang,Huiying Yang
DOI: https://doi.org/10.1016/j.jhep.2008.04.011
IF: 25.7
2008-01-01
Journal of Hepatology
Abstract:Background/Aims: Interferon signaling pathway genes (IPGs) and interferon-stimulated genes (ISGs) are associated with the host response to hepatitis C virus (HCV) infection. We studied single nucleotide polymorphisms (SNPs) in IPGs and ISGs for their associations with response to pegylated interferon alpha-2a (Peg-IFN-alpha) plus ribavirin therapy in HCV genotype-1 infected patients.Methods: A two-stage study design was used. First, out of 118 SNPs selected, 91 SNPs from 5 IPGs and 12 ISGs were genotyped in a cohort of 374 treatment-native HCV patients and assessed for association with sustained virologic response (SVR). Next, 14 potentially functional SNPs from the OASL gene were studied in this cohort.Results: Three OASL SNPs (rs3213545 and rs1169279 from stage I, and rs2859398 from stage II), were significantly associated with SVR [rs3213545: p = 0.03, RR = 1.27 (1.03-1.58); rs.1169279: p = 0.02, RR = 1.32 (1.05-1.65) p = 0.02; rs2859398: p = 0.02, RR = 1.29 (1.04-1.61)] after adjusting for other covariates. Further analysis showed that these three SNPs independently associated with SVR. Additionally, a similar trend towards the associations of these three SNPs with SVR was observed in a smaller, independent HCV cohort consisting of subjects from a number of clinical practice settings.Conclusions: Our study suggests that OASL variants are involved in the host response to IFN-based therapy in HCV patients.(C) 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
-
Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.
Yueqiu Luo,Caixia Jin,Zongxin Ling,Xiaozhou Mou,Qiong Zhang,Charlie Xiang
DOI: https://doi.org/10.1016/j.gene.2012.10.030
IF: 3.913
2013-01-01
Gene
Abstract:Recently, genome-wide associated studies (GWAS) have identified that host genetics IL28B SNPs rs12979860 and rs8099917 were significantly associated with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy. Results from these studies remain conflicting. We conducted this meta-analysis to estimate the overall association of SVR with rs12979860 and rs8099917. We searched the PubMed, Embase, Scholar Google, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure (CNKI) databases for all articles before July 30, 2012. The odds ratio (OR) corresponding to the 95% confidence interval (CI) was used to assess the association. The statistical heterogeneity among studies was assessed with the I2 statistics. Begg's test and Egger's test were performed to evaluate the publication bias. Eventually, twenty studies were selected for the meta-analysis. The IL-28B SNPs rs12979860 genotype CC and rs8099917 genotype TT significantly positive associated with SVR in patients infected chronic HCV genotype 1 to PEG-INF/RBV therapy (OR=4.473, 95% CI=3.814–5.246, OR=5.171, 95% CI=4.372–6.117 respectively). The results suggested that rs12979860 genotype CC and rs8099917 genotype TT could be used as independent predictors of the HCV-1 infected patients.
-
Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Y Chen,H-X Xu,L-J Wang,X-X Liu,R I Mahato,Y-R Zhao
DOI: https://doi.org/10.1111/j.1365-2036.2012.05131.x
IF: 9.524
2012-01-01
Alimentary Pharmacology & Therapeutics
Abstract:Background Interleukin (IL) 28B single nucleotide polymorphisms can predict sustained virological response (SVR) in hepatitis C virus (HCV) patients following pegylated interferon-alpha (PEG IFN-a) and ribavirin treatment. Aim To design a meta-analysis to determine IL28B genotypes', rs12979860 CC and rs8099917 TT, correlation with SVR in PEG IFN-a/ribavirin-treated HCV patients. Methods Meta-analysis was performed in 17 studies of rs12979860 CC vs. CT/TT and 17 of rs8099917 TT vs. TG/GG. Odds ratios (OR) and confidence intervals (95% CI) were calculated by fixed- or random-effects models. Heterogeneity, sensitivity analysis and publication bias were also assessed. Results Of 4252 Asian, Caucasian and African HCV patients analysed for rs12979860, SVR was more frequent in CC (vs. CT/TT; OR similar to=similar to 4.76, 95% CI: 3.157.20). Moreover, CC was associated with SVR for HCV genotype-1 or -4 infections (ORgenotype 1 similar to=similar to 5.52, 95% CI: 3.748.15; ORgenotype 4 similar to=similar to 8.11, 95% CI: 4.1315.93), regardless of ethnicity. Of 4549 Caucasian and Asian HCV patients analysed for rs8099917, SVR was more frequent in TT (vs. TG/GG; OR similar to=similar to 3.31, 95% CI: 2.394.59). Moreover, TT was associated with SVR for HCV-1 (ORgenotype 1 = 4.28, 95% CI: 2.876.38). Rs8099917 TT predictive value was stronger in Asians (ORAsians similar to=similar to 8.09, 95% CI: 5.6311.61; ORCaucasians similar to=similar to 3.00, 95% CI: 2.034.45). Ethnicity stratification revealed that rs8099917 TT had slight predictive value in Asian HCV-2/3 patients (OR similar to=similar to 1.99, 95% CI: 1.093.62). Conclusions IL28B rs12979860 CC and rs8099917 TT are strong SVR predictors for PEG IFN-a/ribavirin-treated HCV-1 patients, regardless of ethnicity. In HCV-2/3, rs12979860 CC has no SVR predictive value, but rs8099917 TT was slightly associated with SVR in Asians.
-
IL28B Genetic Variations Are Associated with Treatment Response of Patients with Chronic Hepatitis C in a Chinese Han Population.
Zhi Xia Dong,Hui Juan Zhou,Xiao Gang Xiang,Si Min Guo,Yan Zhuang,Gang De Zhao,Qing Xie
DOI: https://doi.org/10.1111/1751-2980.12202
2014-01-01
Journal of Digestive Diseases
Abstract:ObjectivesThis study aimed to investigate the association between interleukin 28B (IL28B) single nucleotide polymorphisms (SNPs) and sustained virological response (SVR) in Chinese Han patients with chronic hepatitis C (CHC) and to analyze the correlations between IL28B SNPs and their personal, virological and clinical characteristics.MethodsAltogether 631 Chinese Han individuals, including 297 CHC patients treated with pegylated interferon α plus ribavirin, 14 spontaneous responders to hepatitis C virus (HCV) and 320 healthy controls were enrolled in the study. Two main SNPs of IL28B, rs12979860 and rs8099917, were genotyped using an SNaPshot Multiplex Assay. Associations between IL28B, treatment outcomes and the patients' characteristics were assessed by multivariate logistic regression.ResultsThe proportion of individuals with the rs12979860 CC or rs8099917 TT genotype was similar in the healthy controls and the CHC patients, although all spontaneous responders presented with both genotypes. Patients with IL28B genotypes had a significantly high rate of rapid virological response (RVR) and SVR. Multivariate analysis revealed that the IL28B SNP rs12979860 CC genotype, being aged <40 years and having a non‐genotype 1 (G1) were independent predictors for SVR. The rs12979860 CC genotype and rs8099917 TT genotypes were predictors for RVR. The rs12979860 CC and rs8099917 TT genotypes were more prevalent in patients with a non‐G1 genotype than those with G1 genotype.ConclusionsIL28B rs12979860 CC genotype is a significant predictor for SVR and RVR in Chinese Han patients with CHC. Non‐G1 HCV genotype is associated with favourable IL28Bgenotypes.
-
Prediction of Response to Pegylated-Interferon-α and Ribavirin Therapy in Chinese Patients Infected with Different Hepatitis C Virus Genotype
Xiaoyan Guo,Zhixin Zhao,Junqiang Xie,Qingxian Cai,Xiaohong Zhang,Liang Peng,Zhiliang Gao
DOI: https://doi.org/10.1186/1743-422x-9-123
IF: 5.916
2012-01-01
Virology Journal
Abstract:Abstract Background The standard treatment for patients with chronic hepatitis C (CHC), pegylated interferon-α (PEG-IFN) plus ribavirin (RBV) does not provide a sustained virological response (SVR) in all patients. Genetic variations at the interleukin 28B (IL-28B) locus are important in predicting outcome following therapy in CHC patients. Results We investigated the role of IL28B variations (rs8099917) in response to PEG-IFN-α/RBV treatment and evaluated its association with the risk of the null virological response (NVR) and relapse (REL) in different viral genotypes. We found that the overall distributions of the genotype among the SVR, NVR, and REL groups were significantly different (P<0.001). Patients with the TG genotype had an increased risk of NVR and REL (OR=6.45 95% CI =2.88–14.47, P<0.001 for NVR; OR=2.51, 95% CI =1.29–4.86, P=0.006 for REL, respectively), and patients with the GG genotype had a further increased risk of NVR and REL (OR=12.04, 95% CI =3.21–45.13, P<0.001 for NVR; ,OR=4.30, 95% CI =1.21–15.13, P=0.017 for REL, respectively). G variant genotypes (TG+GG) also had an increased risk of NVR and REL, and there was a significant trend for a dose-effect of G allele on the risk of NVR and REL (P<0.05). The SVR rate in TT higher than in TG+GG was more pronounced in those patients infected with non-G1 compared to the patients infected with G1. The treatment response did differ based on the rs8099917 genotype in patients with different viral genotypes, compared with patients infected with the non-G1, the G1 infected patients had an increased risk of NVR and REL (OR=2.03 95% CI =1.03–4.01, P=0.04 for NVR and OR=2.58, 95% CI =1.35–4.94, P=0.004 for REL, respectively). Moreover, multivariate regression analysis show that the rs8099917 G allele was the only independent factor significantly associated with a NVR and REL. Conclusion This study suggests that host genetic polymorphisms rs8099917 in the vicinity of IL-28B is the most important predictor of treatment response of PEG-IFN-α/RBV for HCV patients in China.
-
Relationship between IL28B gene polymorphisms and peginterferon alpha treatment response in patients with HBeAg-positive chronic hepatitis B
WU Hai-qing,ZHAO Gang-de,QIAN Fang-xing,LAI Rong-tao,XIE Jing-dong,ZHOU Hui-juan,XU Jie,XU Yu-min,LIU Ke-hui,XIE Qing,WANG Hui
DOI: https://doi.org/10.3969/j.issn.1008-1704.2013.06.001
2013-01-01
Abstract:Objective To investigate whether IL28B polymorphisms could affect the peginterferon alpha(PEG-IFN) treatment response in patients with HBeAg positive chronic hepatitis B(CHB).Methods A total of 212 HBeAg-positive GHB patients with PEG-IFN monotherapy were recruited in the study.We collected peripheral blood from patients and extracted their genomic DNA.Polymorphisn of IL28B gene SNPs,rs12980275,rs12979860 and rs8099917 were detected by using the Sequenom Mass Array system.Response was defined as HBV DNA level < 200 IU/mL,HBeAg seroconversion and normal aminotransferase(ALT) levels after 48-week PEG-IFN treatment.Results 212 patients were infected with hepatitis B virus(HBV) genotype B(44.8%) and C(55.2%) with a total response rate of34.9%.The proportions of IL28B genotypes were 77.8%and 22.2%for AA/N-AA(AG or GG) at rs12980275;78.3%and 21.7%for CC/N-CC(CT or TT) at rs12979860;and 79.2%and 20.8%for TT/N-TT(TG/GG) at rs8099917 respectively.For the three SNPs,there were significant differences between the response(R) and non-response(NR) groups both in allele frequencies and genotype distributions(P < 0.05).IL28B wild homozygous genotypes(AA,CC and TT) were independently associated with high rates of R.IL28B genotype was independently associated with R for AA versus N-AA(OR 2.70,95%CI 1.21-6.01;P = 0.015) at rs12980275 after the adjustment of gender,age,HBV genotype,baseline levels of HBV DNA and ALT.There were similar results for rs12979860 CC versus N-CC(OR 2.56,95%CI 1.15-5.67;P = 0.021) and rs8099917 TT versus N-TT(OR 2.80,95%CL 1.236.39;P = 0.015) respectively.Furthermore,one block formed by rs12980275 and rs12979860 was identified in this study.In multivariate analyses,the most common haplotype A-C was independently associated with high rates of R(OR 2.53,95%CI 1.20-5.34;P = 0.015).Conclusion IL28B gene polymorphism was associated with the PEG-IFN treatment response to HBeAg positive CHB patients.1L28B wild homozygous genotypes(AA,TT and CC) were independently associated with high rates of R.
-
IMPACT OF IFNL-3 (IL-28B) POLYMORPHISM ON THE KINETICS OF HBV DNA AND QHBSAG AND HBSAG CLEARANCE DURING THERAPY WITH PEGINTERFERON α-2A IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B, GENOTYPE D
S.V. Fedorchenko,
DOI: https://doi.org/10.61948/prevmed-2024-1-31
2024-01-01
Abstract:Abstract.In recent years baseline predictors of Peg-INF response have been identified, one of the host factors may be include: genetic polymorphism IFNL-3 (IL-28B). The aim of the study. In recent years baseline predictors of Peg-INF response have been identi We investigated the effect of IFNL-3 polymorphism (SNP 12979860, SNP rs8099917) fied, one of the host on HBV DNA kinetics, qHBsAg, SVR rate and HBsAg clearance. as one of the positive prognostic factors of SBB induction. Methods. We investigated the effect of IFNL-3 polymorphism (SNP 12979860, SNP rs8099917) on the kinetics of HBV DNA, qHBsAg, the rate of SVR and HBsAg clearance. 108 patients with HBeAg-negative hepatitis B, genotype D were enrolled into the study. Results. Of 46 patients with CC SNP 12979860, a decline in the concentration of HBsAg>0.5 log10 at 12 weeks of treatment, was noticed in 23 (50.0%) persons in the group of 61 patients, and in 14 (23.0%) with CT alleles (OR=3.36, 95% CI 1.35–8.4, P<0.005). SVR was achieved in 19 (41, 3%) and 12 (19.7%), respectively (OR=3.35, 95% CI 1.12–7.5, P 2 log10 at week 12 was observed in 42 (91.3%), and in 61 patients with CT — in 54 (88.5%) (OR=1.36,CI 0.32–6.75, P=0,0639). At 24 weeks of therapy, the decline in HBV DNA by 2 log10 in the group of patients with CC was detected in 46 (100%) and in those with CT in 61 patients (100%). SVR was achieved in 20 persons (43.5%) and in 11 (18%), respectively (OR=3.5, 95% CI 1.34–9.31, P 0.5 log10 at week 12 was achieved in 27 (42.8%), in the TG group (n=45) — only in 5 (11.1%) (OR=6.0, 95% CI 1.96–21.74, P<0.001). SVR was documented in 24 (38.1%) and 7 (15.6%), respectively (OR=3.34, 95% CI 1.20–10.19, P<0.01). At 12 weeks of therapy in the group with TT alleles, a 2 log10 decline in HBV DNA was observed in 58 individuals (92.0%), in the group with TG — in 40 (88.8%) (OR=1.45, 95% CI 0.31–6.73 P=0.575). At week 24: in TT — 63 patients (100.0%) and in TG — 45 patients (100.0%). SVR was achieved in 23 (36.5%) and 8 (17.7%), respectively (OR=2.66, 95% CI 0.99–7.7, P<0.05). Conclusion. The presented study demonstrates that favorable genetic polymorphism IFNL-3 (SNP 12979860 and SNP rs8099917) is one of the most significant baseline positive predictive factors on SVR induction. Keywords HBeAg-negative chronic hepatitis B, peginterferon, IFNL-3 (IL-28B) polymorphism, sustained virological response, HBsAg.
-
Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China
Renwen Zhang,Cuiping Shoo,Na Huo,Minran Li,Xiaoyuan Xu
DOI: https://doi.org/10.5009/gnl15162
IF: 4.321
2016-01-01
Gut and Liver
Abstract:Background/Aims Several studies have demonstrated that serum interferon-γ-inducible-protein-10 (IP-10) levels at baseline and single nucleotide polymorphisms (SNPs) near the IL28B gene were associated with viral response and treatment outcomes. Our purpose was to assess the combination of pretreatment IP-10 levels with IL28B SNPs as predictors of treatment response to pegylated interferon α-2a plus ribavirin in patients infected with genotype 1 hepatitis C virus in China. Methods Seventy-two patients with chronic hepatitis C without fibrosis/cirrhosis were enrolled in the study. The virologic parameters and baseline serum IP-10 levels were determined. IL-28B genotypes were determined by sequencing. Results In this cohort, serum baseline IP-10 levels lower than 426.7 pg/mL could predict rapid virological response/sustained virological response (SVR). Patients carrying favorable IL28B SNP genotypes had higher SVRs than did those carrying unfavorable variants (IL28B rs12979860, p=0.002; IL28B rs8099917, p=0.020). Combining both baseline IP-10 and IL28B SNPs could improve the prediction of SVR in favorable allele carriers of IL28B, rs12979860 CC and rs8099917 TT. Serum baseline IP-10 levels and IL28B genotypes were independent predictors of SVR. Conclusions Our study shows that the combination of baseline serum IP-10 levels and the determination of IL28B SNPs increase the predictability of SVR rates in this cohort.
-
Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis
Nicolae-Catalin Mechie,Christian Röver,Silke Cameron,Ahmad Amanzada
DOI: https://doi.org/10.4254/wjh.v6.i10.759
2014-10-03
Abstract:AIM: To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and pegylated interferon-$\alpha$ (Peg-INF-$\alpha$) based triple-therapy.
METHODS: We searched PubMed, the Cochrane Library and Web of Knowledge for studies regarding the interleukin 28B (IL-28B)-genotype and protease-inhibitor based triple-therapy. Ten studies with 2707 patients were included into this meta-analysis. We used regression methods in order to investigate determinants of SVR.
RESULTS: IL-28B-CC-genotype patients achieved higher SVR rates (odds 5.34, CI: 3.81-7.49) than IL-28B-non-CC-genotype patients (1.88, CI: 1.43-2.48) receiving triple-therapy. The line of therapy (treatment-naïve or -experienced for Peg-INF-$\alpha$) did not affect the predictive value of IL-28B (p=0.1). IL-28B-CC-genotype patients treated with protease inhibitor-based triple-therapy consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir showed odds of 1.86, 9.77, 4.51 and 0.89, respectively. The odds for CC genotype patients treated with Faldaprevir cannot be quantified, as only a single study with a 100% SVR rate was available.
CONCLUSION: IL-28B-SNP predicts the outcome for chronic HCV genotype-1 patients receiving protease inhibitor-based triple-therapy. The predictive value varies between the different protease inhibitors.
Quantitative Methods,Applications
-
Association of Genetic Variation in Il28B with Hepatitis C Treatment-Induced Viral Clearance in the Chinese Han Population
Xiang-Wei Liao,Yun Ling,Xin-Hua Li,Yue Han,Shen-Ying Zhang,Lei-Lei Gu,De-Ming Yu,Bi-Lian Yao,Dong-Hua Zhang,Gen-Di Jin,Zhi-Meng Lu,Qi-Ming Gong,Xin-Xin Zhang
DOI: https://doi.org/10.3851/imp1703
2010-01-01
Antiviral Therapy
Abstract:Background Genome-wide association studies have recently shown that the rs12979860 polymorphism in IL28B is associated with the response to chronic hepatitis C treatment. The aim of this study was to investigate whether rs12979860 could be used as a predictive marker for end-of-treatment response (ETR) or sustained virological response (SVR) in the Chinese Han population. Methods The rs12979860 genotype was detected in 259 individuals infected with HCV by DNA sequencing. Among them, 120 patients were administered complete pegylated interferon-α and ribavirin combination therapy and 92 patients were followed for 24 weeks after the cessation of treatment and were divided into different groups according to outcomes of treatment. Results The rs12979860 genotype CC was the primary genotype (87.64%, 227/259) and genotype TT was found in only one individual within this cohort. The patients with the rs12979860 genotype CC had higher rates of ETR ( P=0.0044) and SVR ( P=0.0046) than the patients with N-CC (CT or TT). In multivariate analyses, the rs12979860 genotype CC was associated with a substantial difference in rates of achieving ETR (odds ratio [OR] 8.983, 95% confidence interval [CI] 2.173–37.145; P=0.0024) and SVR (OR 24.298, 95% CI 2.27–259.90; P=0.0083). Conclusions This study demonstrated for the first time that the rs12979860 variation in IL28B could be a predictor of ETR and SVR in Chinese Han patients infected with HCV. The high frequency of the rs12979860 genotype CC might explain why the SVR rate is higher than that of the average global population.
-
No Association Between IFNL3 (IL28B) Genotype and Response to Peginterferon Alfa-2A in HBeAg-positive or -Negative Chronic Hepatitis B.
Lai Wei,Heiner Wedemeyer,Yun-Fan Liaw,Henry Lik-Yuen Chan,Teerha Piratvisuth,Patrick Marcellin,Jidong Jia,Deming Tan,Wan-Cheng Chow,Maurizia R. Brunetto,Moises Diago,Selim Gurel,Viacheslav Morozov,Hua He,Yonghong Zhu,Cynthia Wat,Bernadette Surujbally,Alexander J. Thompson
DOI: https://doi.org/10.1371/journal.pone.0199198
IF: 3.7
2018-01-01
PLoS ONE
Abstract:BACKGROUND & AIMS:It has yet to be firmly established whether host IFNL3 (IL28B) genotype influences interferon responsiveness in patients with chronic hepatitis B. We investigated associations between single-nucleotide polymorphisms (SNPs) in the IFNL3 region and response to peginterferon alfa-2a in 701 patients enrolled in three large, randomized, international studies.METHODS:Responses were defined as hepatitis B surface antigen (HBsAg) loss and/or hepatitis B e antigen (HBeAg) seroconversion plus hepatitis B virus (HBV) DNA <2000 IU/ml in HBeAg-positive patients, and HBsAg loss and/or HBV DNA <2000 IU/ml in HBeAg-negative patients (24 weeks after end of treatment). Associations between treatment response and the number of copies of the poor-response allele at three SNPs (rs8099917, rs12980275, rs12979860) were explored with logistic regression models in Asian and white patients.RESULTS:The HBeAg-positive and -negative populations comprised 465 (92% Asian, 50% HBV genotype C) and 236 (79% Asian, 41% HBV genotype C) patients, respectively, and had respective response rates of 26% and 47%. The IFNL3 genotype was strongly associated with ethnicity. There was no association between IFNL3 genotype and treatment response in HBeAg-positive or -negative patients. Independent predictors of treatment response were: sex, HBV DNA level and alanine aminotransferase level in HBeAg-positive Asian patients; age in HBeAg-negative Asian patients; and HBV DNA in HBeAg-negative white patients.CONCLUSIONS:This is the largest analysis to date of associations between IFNL3 genotype and peginterferon response in patients with chronic hepatitis B. The data suggest that IFNL3 polymorphism is not a major determinant of the response to peginterferon alfa-2a in either HBeAg-positive or HBeAg-negative patients.
-
[Investigation of the Relationship Between IL28B Polymorphisms and Plasma IL28B Levels in Patients with Chronic Hepatitis B or C]
Zeynep Koç Kuralay,Esra Tuğ,Işıl Fidan
DOI: https://doi.org/10.5578/mb.20219807
Abstract:Some single nucleotide polymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) may increase susceptibility to infection and chronicity in humans with hepatitis B and C viruses. In our study, we aimed to investigate the prevalence of rs12979860, rs8099917 and rs12980275 SNPs in IL28B in patients with hepatitis B (HBV) or hepatitis C Virus (HCV) infection and to determine the relationship of these polymorphisms with plasma IL28B levels. For this purpose, 64 HBV-infected and 66 HCV-infected patients and 70 healthy individuals were included in the study. The SNPs were investigated by real time PCR (Polimerase Chain Reaction, Rt-PCR) using TaqMan SNP Genotyping Assay. The plasma levels of IL28B were detected by 'Enzyme Linked Immunosorbent Assay (ELISA)'. The frequencies of the rs12980275AG genotype and G allele (p= 0.003 and p= 0.04, respectively), and the rs12979860CT genotype and T allele (p= 0.01 and p= 0.04, respectively) were lower in HBV-infected patients. In HCV-infected patients, the rs8099917TG genotype and G allele frequencies (p= 0.04) were higher and the TGG haplotype showed a statistically significant difference (p= 0.04). The mean of IL28B plasma levels were higher in the control group than the HBV or HCV-infected patient groups (p= 0.001 and p= 0.01, respectively). However, HBV-infected patients with the rs12980275AG genotype showed a significant difference in plasma IL28B levels compared to the other genotypes (p= 0.0001) and these patients had lower viral loads (<105 IU/ml). According to the results of the study, it can be stated that rs12979860CT and rs12980275AG genotypes may play a role in preventing the chronicity of HBV infection, while rs8099917TG genotype may contribute to the transformation of HCV infection into chronic infection. In this study, it was observed that the presence of the G allele for the rs8099917 polymorphism could be evaluated as a risk allele for chronic HCV infection and that the TGG haplotype could have a strong predictive effect on increasing susceptibility to chronic HCV infection. It is recommended to evaluate the genotypic distribution of IL28B before treatment because of its prognostic significance in HBV or HCV infected patients. In HBV infection, the rs12980275AG genotype which is thought to have a protective effect by limiting viral replication with increased plasma IL28B levels, can be used as a good prognostic factor. These polymorphisms could be used as biomarkers to predict the clinical consequences of the patients infected with HBV or HCV, to take precautions to prevent the chronicity of the infection and its complications, and to develop new molecular targeted therapies with further research.
-
Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta-analysis.
Ming Yang,Hui-Ying Rao,Bo Feng,Wei Zhang,Lai Wei
DOI: https://doi.org/10.1111/jgh.12233
2013-01-01
Journal of Gastroenterology and Hepatology
Abstract:Background and Aim Recent studies suggested that interleukin 28B (IL28B) polymorphisms may affect spontaneous clearance (SC) of hepatitis C virus (HCV) infection. Our purpose was to update the meta-analysis to reevaluate the impact of IL28B rs12979860 and rs8099917 polymorphisms on SC in patients infected with HCV. Methods We searched PubMed, Web of Science, and Embase up to February 2013. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated by fixed- or random-effects models. Heterogeneity, sensitivity analysis, and publication bias were also assessed. Results Seventeen eligible papers were involved in this study. The SC rate was higher in patients with the rs12979860 CC (vsCT/TT OR=2.98, 95% CI 2.53-3.50) and rs8099917 TT (vsGT/GG OR=2.80, 95% CI 2.23-3.51) in the IL28B polymorphisms. Ethnicity stratification revealed that rs12979860 CC was associated with SC for Caucasians (vsCT/TT OR=3.05, 95% CI 2.67-3.49), Asians (vsCT/TT OR=1.88, 95% CI 1.33-2.66), and Africans (vsCT/TT OR=3.15, 95% CI 2.39-4.15); rs8099917 TT was associated with SC for Caucasians (vsGT/GG OR=2.48, 95% CI 1.96-3.15). Conclusions IL28B rs12979860 and rs8099917 single nucleotide polymorphisms are significantly associated with SC of HCV infection. The predictive value of rs12979860 CC was stronger in Caucasians and Africans than in Asians.
-
Influence Ofil28bandmxagene Polymorphisms on HCV Clearance in Han Chinese Population
Feng Zang,Ming Yue,Yinan Yao,Mei Liu,Haozhi Fan,Yue Feng,Xueshan Xia,Peng Huang,Rongbin Yu
DOI: https://doi.org/10.1017/s0950268817002928
2017-01-01
Epidemiology and Infection
Abstract:The high rate of chronic hepatitis C (CHC) was one of the key issues of global public health concern. Interferon (IFN)-λ relevant genes were in the antiviral treatment pathway, not only influenced hepatitis C virus (HCV) spontaneous clearance, but also affected the IFN-mediated viral clearance. The aim of this study was to identify the association of interleukin 28B (IL28B), myxovirus resistance A (MxA) gene polymorphisms with HCV spontaneous clearance and therapeutic response in Chinese CHC patients. IL28B and MxA gene genotypes were detected among 231 CHC carriers, 428 subjects with HCV spontaneous clearance and 662 CHC patients with pegylated IFN-α and ribavirin (pegIFN-α/RBV) treatment. Patients with MxA rs2071430 TT genotype were more likely to develop HCV infection chronicity (additive model: odds ratio (OR) 1.22, 95% confidence interval (CI) 1.01-1.48, P = 0.042). IL28B rs1298075 variant genotypes (additive model: OR 0.58, 95% CI 0.34-0.98, P = 0.040) and MxA rs17000900 variant genotypes (additive model: OR 0.54, 95% CI 0.30-0.99, P = 0.048) were less likely to achieve a sustained virological response. The life table indicated that patients with IL28B rs1298075 AG genotype were slower to achieve a viral load 106 copies/ml (all P < 0.05). This study illustrated that the carriage of IL28B rs12980275 AA had a positive effect on treatment response to pegIFN-α/RBV among Chinese CHC patients.
-
IL 28 B Genetic
X. Shi,Y. Pan,Moli Wang,Dongsheng Wang,Wan-Sheung Li,Tao Jiang,Peng Zhang,Xiumei Chi,Yanfang Jiang,Yanhang Gao,Jin Zhong,Bing Sun,Damo Xu,Jing Jiang,Junqi Niu
2012-01-01
Abstract:Background: The interleukin-28B gene (IL28B) locus has been associated with host resistance to hepatitis C virus (HCV) infection and response to PEG-IFN/RBV treatment in western populations. This study was to determine whether this gene variant is also associated with spontaneous clearance of HCV infection, treatment response and IL-28B protein production in Chinese patients. Methods: We genotyped IL28B genetic variations (rs12980275, rs8103142, rs8099917 and rs12979860) by pyrosequencing DNA samples from cohorts consisting of 529 subjects with persistent HCV infection, 196 subjects who cleared the infection, 171 healthy individuals and 235 chronic HCV patients underwent IFN/RBV treatment. The expression of IL-28B were measured by ELISA and RT-PCR. Results: We found that the four IL28B variants were in complete linkage disequilibrium (r2 = 0.97–0.98). The rs12979860 CC genotype was strongly associated with spontaneously HCV clearance and successful IFN/RBV treatment compared to the CT/TT. IL-28B levels in persistent HCV patients were significantly lower than subjects who spontaneously resolved HCV and healthy controls and were also associated with high levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). IL-28B levels were also significantly lower in individuals carrying T alleles than CC homozygous. Conclusions: Thus, the rs12979860-CC variant upstream of IL28B gene is associated with spontaneous clearance of HCV, susceptible to IFN/RBV treatment and increased IL-28B levels in this Chinese population. Citation: Shi X, Pan Y, Wang M, Wang D, Li W, et al. (2012) IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population. PLoS ONE 7(5): e37054. doi:10.1371/journal.pone.0037054 Editor: Kui Li, University of Tennessee Health Science Center, United States of America Received July 3, 2011; Accepted April 12, 2012; Published May 23, 2012 Copyright: 2012 Shi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This study was supported by grants from the Shanghai Pasteur Health Research Foundation (SPHRF2009001), the Eleventh 5-year National Key Programs on Infectious Disease (2008ZX10002-014), the National Natural Science Foundation of China under grants No 81001312/H1005 and 81072347/H2609 and the Graduate Innovation Fund of Jilin University (No. 20101036). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * E-mail: junqiniu@yahoo.cn (JN); jiangjing19702000@yahoo.cn (JJ) . These authors contributed equally to this work.
-
Host IL28B and Viral Genotype Differences in Responses to Antiviral Therapy Efficacy in Chronic Hepatitis C
廖祥伟,凌云,李新华,韩悦,张申英,谷雷雷,张东华,金根娣,陆志檬,龚启明,张欣欣
DOI: https://doi.org/10.16505/j.2095-0136.2011.01.011
2011-01-01
Abstract:Objective To investigate host IL28B and viral genotype differences in responses to antiviral therapy efficiency in chronic HCV patients.Methods The study had 120 patients,who were able to complete the full course of combination therapy with pegylated interferon-α and ribavirin.Ninety-two patients were followed for 24 weeks after the cessation of treatment.The treatment efficiency was evaluated with end-of-treatment response(ETR) and sustained virological response(SVR).A logistic regression model was applied to analyze the association of treatment efficacy with host IL28B and viral genotypes.Results The higher rates of ETR(P= 0.001 4) and SVR(P= 0.000 7) were observed in HCV genotype 1b infected patients with IL28B genotype CC than the rates in HCV genotype 1b infected patients with IL28B genotype N-CC.However,there was no significant difference in treatment efficiency between HCV genotype N-1b infected patients with IL28B genotype CC and HCV genotype N-1b infected patients with IL28B genotype N-CC.In the participants with IL28B genotype N-CC,the HCV genotype N-1b infected patients had higher rates of ETR(P=0.035 0) and SVR(P=0.022 2) than HCV genotype 1b infected patients did.However,there was no significant difference in treatment efficiency between IL28B genotype CC patients infected with HCV genotype 1b infection and IL28B genotype CC patients infected with N-1b.Conclusions HCV and host IL28B genotypes were associated with outcomes of patients treated with pegylated interferon-α and ribavirin.The determination of host IL28B and HCV genotypes could provide a reliable basis for individual therapy and predicting treatment efficacy.